AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02997982
Drug: Valaciclovir 500Mg Tablet
RxNorm normalized name: valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
Trial: NCT02419820
Drug: APD791
RxNorm normalized name: APD791
DrugBank: APD791 (DB05227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temanogrel
Trial: NCT02419820
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel
Trial: NCT02419820
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin
Trial: NCT02419820
Drug: Placebo for APD791
DrugBank: APD791 (DB05227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for APD791
Trial: NCT00445770
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg twice weekly, subcutaneous injection for 52 weeks
Trial: NCT00445770
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg, twice weekly, subcutaneous injection for 52 weeks
Trial: NCT00965419
Drug: Edivoxetine
RxNorm normalized name: Edivoxetine
DrugBank: Edivoxetine (DB09184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ \[No NCT number\]) and (LNBF \[NCT00922636\]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
Trial: NCT03857542
Drug: Pilocarpine HCl Ophthalmic Solution
RxNorm normalized name: pilocarpine hydrochloride Ophthalmic Solution
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.
Trial: NCT04412707
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral versus central administration
Trial: NCT04412707
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets
Trial: NCT03044808
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03044808
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05840536
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
Trial: NCT02386501
Drug: ADXS31-164
DrugBank: ADXS-31164 (DB17325)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00551603
Drug: switch (epoetinum beta, darbepoetinum)
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
Trial: NCT02831933
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prodrug of the antiviral drug acyclovir
Trial: NCT02831933
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
Trial: NCT01831674
Drug: Metformin Hydrochloride Extended-Release Tablets USP 750
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
Trial: NCT01969435
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01969435
Drug: Etoposide phosphate
RxNorm normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01969435
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01969435
Drug: Melphalan HCl (propylene glycol-free)
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04751188
Drug: Bezafibrate 200 MG Oral Tablet
RxNorm normalized name: bezafibrate 200 MG Oral Tablet
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate one tablet every 12 hours for six months.
Trial: NCT04751188
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At a dose of 13 to 15 mg per Kg per day.
Trial: NCT02215135
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW\> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
Trial: NCT04204044
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin Hydrochloride is used in PCO
Trial: NCT04204044
Drug: Myo-inositol
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myo inositol used in PCO
Trial: NCT01270438
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00518271
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02685228
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine 5mg/m2,d1-d5;
Trial: NCT02685228
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine 1.0g/m2, d8,d15,d22
Trial: NCT01673620
Drug: Montelukast 10 mg/loratadine 10 mg
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg/loratadine 10 mg tablet administered once daily
Trial: NCT00988949
Drug: PF-04455242
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral 18 mg dose of PF-04455242.
Trial: NCT00988949
Drug: spiradoline
RxNorm normalized name: Spiradoline
DrugBank: Spiradoline (DB12704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
Trial: NCT00988949
Drug: PF-04455242
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 30 mg oral dose of PF-04455242.
Trial: NCT00949910
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
Trial: NCT04397562
Drug: Levilimab
RxNorm normalized name: Levilimab
DrugBank: Levilimab (DB16387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levilimab 324 mg
Trial: NCT01890408
Drug: wound infusion ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours.
Trial: NCT02522325
Drug: Phendimetrazine
RxNorm normalized name: Phendimetrazine
DrugBank: Phendimetrazine (DB01579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phendimetrazine will be administered in divided doses twice daily.
Trial: NCT02522325
Drug: Cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine will be administered during experimental sessions.
Trial: NCT01318148
Drug: caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous application of caspofungin
Trial: NCT04500886
Drug: rhG-CSF
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhG-CSF can increase the proliferation and differentiation of neutrophils from committed progenitor cells, induces maturation, and enhances the survival and function of mature neutrophils.
Trial: NCT01012544
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
Trial: NCT03458650
Drug: LXI-15028 50mg
RxNorm normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
Trial: NCT03458650
Drug: LXI-15028 100mg
RxNorm normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
Trial: NCT03458650
Drug: LXI-15028 200mg
RxNorm normalized name: LXI-15028
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
Trial: NCT00388258
Drug: Alvimopan
RxNorm normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00856258
Drug: PF 03882845 and Placebo
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
Trial: NCT00856258
Drug: PF 03882845 and Placebo
RxNorm normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
Trial: NCT00303615
Drug: Fluoxymesterone 10 mg
RxNorm normalized name: fluoxymesterone 10 MG
DrugBank: Fluoxymesterone (DB01185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00303615
Drug: Anastrozole 1 mg
RxNorm normalized name: anastrozole 1 MG
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005085
Drug: becatecarin
RxNorm normalized name: Becatecarin
DrugBank: Becatecarin (DB06362)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01611766
Drug: Salvage Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of postoperative chemotherapy
Trial: NCT04811001
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets
Trial: NCT04811001
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
Trial: NCT01883869
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02752724
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Trial: NCT02752724
Drug: Methohexital
RxNorm normalized name: Methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
Trial: NCT00352313
Drug: ATN-161
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00352313
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00696436
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks.
Trial: NCT00696436
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks.
Trial: NCT00696436
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks.
Trial: NCT00696436
Drug: Olmesartan
RxNorm normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks.
Trial: NCT00833807
Drug: Nab-Paclitaxel (Abraxane)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days.
Trial: NCT03943446
Drug: TAK-018
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-018 immediate-release tablets.
Trial: NCT01281189
Drug: Dexpramipexole
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet 150mg twice daily for up to 18 months.
Trial: NCT03200093
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
Trial: NCT02812719
Drug: Glycolic acid peel alone
RxNorm normalized name: orange peel extract
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals
Trial: NCT02467023
Drug: Muscle Biopsy Medication: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
Trial: NCT02812719
Drug: Glycolic and salicylic acid peel
RxNorm normalized name: glycol salicylate / nonivamide / salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals.
Trial: NCT01454479
Drug: Lapatinib and ixempra
RxNorm normalized name: IXEMPRA
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ixabepilone 40 mg/m2 Lapatinib 250 mg
Trial: NCT00890383
Drug: tetrastarch (Voluven)
RxNorm normalized name: Hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goals directed volume therapy for severe trauma resuscitation
Trial: NCT01313897
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
Trial: NCT03652051
Drug: AZR-MD-001 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZR-MD-001 is an ophthalmic ointment
Trial: NCT03652051
Drug: AZR-MD-001 High Dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 is an ophthalmic ointment
Trial: NCT06377722
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
Trial: NCT04235439
Drug: Gan & Lee Insulin Lispro Injection
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
Trial: NCT01823770
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
Trial: NCT01273493
Drug: Trabectedin
RxNorm normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trabectedin 0.58 or 1.3 mg/m\^2 (or adjusted dose) i.v. will be administered on Day 1.
Trial: NCT01273493
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be administered as 20 mg/m\^2, 30 minutes prior to trabectedin.
Trial: NCT00003219
Drug: perillyl alcohol
RxNorm normalized name: Perillyl alcohol
DrugBank: Perillyl alcohol (DB15289)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00459862
Drug: pazopanib hydrochloride
RxNorm normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00001777
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02501902
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
Trial: NCT02501902
Drug: Nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
Trial: NCT01972854
Drug: riboflavin solution
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12% riboflavin ophthalmic solution
Trial: NCT00124189
Drug: GRN163L
RxNorm normalized name: Grn163l
DrugBank: Grn163l (DB05036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly intravenous infusion
Trial: NCT02513771
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
Trial: NCT02008773
Drug: Valacyclovir HCI 500 mg tablets
RxNorm normalized name: valacyclovir 500 MG
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
Trial: NCT02374567
Drug: Phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02374567
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02374567
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no